Bortezomib Inhibits Lung Fibrosis and Fibroblast Activation without Proteasome Inhibition.

Penke, Loka Raghu Kumar; Speth, Jennifer; Wettlaufer, Scott; Draijer, Christina; Peters-Golden, Marc

Penke, Loka Raghu Kumar; Speth, Jennifer; Wettlaufer, Scott; Draijer, Christina; Peters-Golden, Marc.

Affiliation

Penke LRK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and.
Speth J; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and.
Wettlaufer S; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and.
Draijer C; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and.
Peters-Golden M; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and.

Am J Respir Cell Mol Biol ; 66(1): 23-37, 2022 01.

Article in En | MEDLINE | ID: mdl-34236953

Subject(s)

Bortezomib/therapeutic use; Fibroblasts/pathology; Proteasome Inhibitors/pharmacology; Pulmonary Fibrosis/drug therapy; Pulmonary Fibrosis/pathology; Adult; Apoptosis/drug effects; Bleomycin; Bortezomib/pharmacology; Cell Dedifferentiation/drug effects; Cell Line; Cell Proliferation/drug effects; Dual Specificity Phosphatase 1/metabolism; Fibroblast Growth Factor 2/pharmacology; Fibroblasts/drug effects; Humans; Myofibroblasts/drug effects; Myofibroblasts/pathology; NF-kappa B/metabolism; Prostaglandins/metabolism; Signal Transduction/drug effects; Transcription, Genetic/drug effects; Transforming Growth Factor beta/metabolism; fas Receptor/metabolism

Key words

bortezomib; fibroblast activation; proteasome; pulmonary fibrosis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pulmonary Fibrosis / Fibroblasts / Proteasome Inhibitors / Bortezomib Type of study: Guideline / Prognostic_studies Limits: Adult / Humans Language: En Year: 2022 Type: Article

Fulltext

XML

PubMed Links

Search on Google